Therapeutic Indications

Apalutamide is indicated for:

Non-metastatic castration-resistant prostate cancer (nmCRPC)

Men inly, only Adults (18 years old or older)

Apalutamide is indicated in adult men for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Oral - 240 mg once daily

Metastatic hormone-sensitive prostate cancer (mHSPC)

Men inly, only Adults (18 years old or older)

Apalutamide is indicated in adult men for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT).

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Oral - 240 mg once daily

Contraindications

Active ingredient Apalutamide is contraindicated in the following cases:

Pregnancy

No gender/age discrimination

Apalutamide is contraindicated in women who are or may become pregnant. Based on its mechanism of action, apalutamide may cause foetal harm when administered during pregnancy. There are no data available from the use of apalutamide in pregnant women. Animal reproductive studies have not been conducted with apalutamide.